33 results about "Thrombolysis" patented technology

The invention discloses a plasmin lumbrukinase peptide dietary therapy formula suitable for rehabilitation of cardiovascular and cerebrovascular diseases, blood circulation promoting, blood stasis removing, thrombolysis, collateral dredging and microcirculation improving, and relates to the technical field of medicine and food homology dietary therapy. Soybean protein isolate and earthworm protein are used as core thrombolytic active raw materials, isomaltooligosacharide, xylitol, German Jilida collagen peptide, soybean peptide powder, Belgian imported inulin, red yeast rice and natto powder are compounded, microcrystalline cellulose and magnesium stearate are used as auxiliary materials, and probiotics / metabiotics strains such as rhamnolactobacilli JYLR-005 and the like can be selectively added. The raw materials have a synergistic effect through precise matching, plasmin and lumbrukinase peptide in earthworm protein can directly dissolve thrombus fibrin, natto powder and red yeast rice assist in lowering lipid and dissolving thrombus, multiple active peptides and prebiotics regulate intestinal microecology to improve microcirculation of the whole body, probiotics / metabiotics further strengthen the metabolic capacity of the body, no chemical medicine is added in the whole process, and the traditional Chinese medicine composition is free of toxic and side effects and free of toxic and side effects. The safety is high; the dietary therapy composition can achieve postoperative rehabilitation conditioning of cardiovascular and cerebrovascular diseases through daily consumption, effectively promote blood circulation to remove blood stasis, dissolve thrombus and dredge collaterals, improve microcirculation and relieve various discomfort caused by blood vessel clogging, raw materials are easy to obtain, compatibility is scientific, and the dietary therapy composition is suitable for large-scale production and popularization.

The invention relates to a mesenchymal stem cell-nano knapsack system, preparation thereof and application of the mesenchymal stem cell-nano knapsack system in treatment of cerebral arterial thrombosis. The invention constructs an engineered mesenchymal stem cell-thrombin responsive nano knapsack for sequential targeted delivery of rtPA, antioxidant active molecules and MSCs for ischemic stroke treatment. In a sequential delivery mode, firstly, a thrombus site is targeted, the thrombin is responded to release rtPA for thrombolysis, brain blood supply is recovered, and the rtPA thrombolysis efficiency is improved. The antioxidant active molecules are entrapped on the erythrocyte membrane bionic nanoparticles, are loaded on the surfaces of the MSCs in a knapsack form, penetrate through BBB and tend to damage ischemic penumbra and release the antioxidant active molecules by means of central transport and inflammatory homing effects of the MSCs, on one hand, oxidative stress is inhibited, a microenvironment beneficial to activity maintenance is provided for the MSCs, and on the other hand, the antioxidant active molecules are released; and meanwhile, the medicine cooperates with MSCs to play a role in protecting injured nerve and blood vessel units, so that the treatment effect on cerebral arterial thrombosis is improved.

The invention provides a composition for improving the thrombolysis capacity of a human body, a preparation method and application thereof.The composition is prepared from, by weight, 5-30 parts of earthworm protein, 30-120 parts of hippophae rhamnoides total flavone extract, 50-150 parts of silymarin extract, 20-80 parts of maltodextrin and 15-60 parts of pregelatinized starch, the earthworm protein activates a fibrinolytic system to promote t-PA to release and dissolve thrombus, and the hippophae rhamnoides total flavone extract activates the fibrinolytic system to promote t-PA to release and dissolve thrombus; the hippophae rhamnoides total flavonoids regulate the ratio of PGI2 / TXA2 to inhibit platelet aggregation and reduce blood fat, the silymarin protects the liver function to enhance LDL-C metabolism clearing, the hippophae rhamnoides total flavonoids, the silymarin and the hippophae rhamnoides total flavonoids cooperate to form a thrombolysis-antithrombosis-metabolism regulation three-dimensional intervention system, a whole-course low-temperature mixing direct tabletting process is adopted

This invention relates to a pharmaceutical composition and its application for treating acute ischemic stroke. The pharmaceutical composition for treating acute ischemic stroke comprises separately packaged tissue-type plasminogen activator citPA5 and a platelet aggregation inhibitor. Its beneficial effects include significantly improving cerebral blood flow recovery, shortening thrombolysis time, reducing infarct volume, and improving neurological function without increasing the risk of bleeding, demonstrating a good synergistic thrombolytic effect.

The invention discloses a traditional Chinese medicine composition for treating and preventing cardiovascular and cerebrovascular diseases and postoperative repair and recuperation based on classic famous prescription, and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The composition is prepared by combining a prescription based on coptis and colla corii asini decoction, cassia twig decoction, cinnamomum cassia and aconitum carmichaeli decoction and poria cocos, cinnamomum cassia and aconitum carmichaeli decoction, as well as poria cocos, cinnamomum cassia and aconitum carmichaeli decoction, and poria cocos and aconitum carmichaeli decoction, and poria cocos and aconitum carmichaeli decoction, and poria cocos and aconitum carmichaeli decoction, and poria cocos and aconitum carmichaeli decoction and poria cocos and In the formula, ligusticum wallichii and earthworm promote blood circulation to remove blood stasis, dredge collaterals and dissolve thrombus; hawthorn and lotus leaf are used for dissolving turbidity, lowering lipid and regulating blood fat and cholesterol; the poria cocos and the rhizoma alismatis are used for clearing damp and promoting diuresis. The whole formula has the effects of warming yang, dredging collaterals, nourishing yin and blood, promoting blood circulation to remove blood stasis, dissolving turbidity, reducing lipid, calming the heart, soothing the nerves and the like, can be used for treating cardiovascular and cerebrovascular diseases, conditioning dyslipidemia, preventing atherosclerosis and postoperative repair and nursing at the same time, is wide in application range and high in safety, can be prepared into various oral dosage forms, and has a good application prospect.

The application discloses a sports nutrition food composition for blood vessel health and post-exercise recovery. Each 40g contains soybean protein isolate, whey protein, resistant dextrin, inulin, ginkgo biloba extract, hawthorn extract, grape seed extract, sea buckthorn peptide, natto powder (containing natto kinase), coenzyme Q10, natural vitamin E, vitamin C, bacillus subtilis DE111 and mineral probiotic premix. The application realizes blood vessel cleaning and post-exercise recovery through the synergy of multiple pathways such as direct thrombolytic effect of natto kinase, anti-platelet aggregation of ginkgo biloba / hawthorn / grape seed, protection of blood vessel endothelium by coenzyme Q10 / VE / VC, and regulation of intestinal tract by bacillus subtilis DE111. In-vitro thrombolysis experiment shows that the composition has clear fibrinolytic activity. All components meet the national standard of sports nutrition food, are safe and compliant, and are suitable for people with thrombosis risk and people who need blood vessel repair after high-intensity exercise.

The utility model relates to a thrombolysis catheter which comprises an outer catheter provided with a main body tube, the far end side of the main body tube is provided with a perfusion section, and the perfusion section is provided with a plurality of perfusion holes arranged at intervals in the axial direction; the inner pushing pipe is provided with a pipe body, and the pipe body is arranged in the main body pipe in a sliding and penetrating mode so as to selectively cover at least part of the perfusion holes and further adjust the effective length of the perfusion section; the core rod is arranged in the inner push tube and the outer guide tube in a sliding and penetrating manner; the plugging device comprises a capturing part located on the far-end side and a plugging part located on the near-end side, the capturing part and the plugging part are connected with each other, and the far end of the core rod is fixedly connected with the near end of the plugging part. The thrombolysis catheter can capture thrombus falling from the blood vessel wall, and is simple to operate and high in thrombus removal efficiency.

Provided herein are plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or disorder associated with elevated PAI-1. The disclosure includes, but is not limited to, the use of such compounds to prevent or reduce thrombosis and fibrosis, to promote thrombolysis, and to modulate lipid metabolism and treat diseases or disorders associated with elevated PAI-1, cholesterol, or lipid levels. 20 24 20 26 17 22 A pr 2 02 4 A B S T R A C T 2 0 2 4 2 0 2 6 1 7 2 2 A p r 2 0 2 4

The present disclosure provides use of icaritin in preparing a drug for preventing and treating a bleeding disorder and belongs to the field of medicine. The icaritin can relieve platelet dysfunction, shorten thromboplastin time, and promote blood coagulation, and can be used for preventing and treating the bleeding disorder, especially for treating hemorrhagic transformation after cerebral infarction, gastrointestinal bleeding caused by a thrombolytic or antithrombotic drug for cerebral infarction, or a bleeding complication of a thrombolytic or antithrombotic drug for myocardial infarction.

Provided herein are methods for safe and effective thrombolysis in therapy for human subjects with symptoms of a potential stroke or acute myocardial infarction (“AMI”) using a sequential administration of a low dose bolus of human tissue plasminogen activator (“tPA”) followed by an infusion of a mutant form of human pro-urokinase (“proUK”).

The embodiment of the invention discloses an evaluation method for an in-vitro hypotonic thrombolysis effect and application of the evaluation method. The method comprises: providing a first blood clot; mixing the second blood clot with hypotonic saline water, standing, and collecting the second blood clot; the thrombolysis effect is evaluated by comparing the performance differences between the first blood clots and the second blood clots. The change condition of blood plaque dissolution under the hypotonic condition is explored, and an experimental platform is laid for establishing a new plaque dissolution method. The method provided by the invention is high in operability and has a good application prospect.

The invention relates to a pharmaceutical composition with an effect of improving blood-brain barrier injury after cerebral infarction thrombolysis. The pharmaceutical composition is prepared from the following raw material medicines in parts by weight: 1-100 parts of astragaloside, 0.25-25 parts of tanshinol and 1-100 parts of notoginsenoside R1.

Hemorrhage and vascular instability can be induced by thrombolytic and anti-coagulant therapies. Presented herein, in certain aspects, are methods for the treatment and / or prevention of hemorrhage and vascular instability that comprise administering a compound disclosed herein to a subject in need thereof.

This invention discloses a traditional Chinese medicine (TCM) for treating neck, back, and leg pain, as well as cardiovascular and cerebrovascular diseases, and its preparation method, belonging to the field of TCM technology. The TCM is composed of various medicinal herbs, including peach kernel, safflower, angelica, red peony root, leech, and earthworm, in specific weight proportions. Its core treatment principle is "activating blood circulation and removing blood stasis, clearing the meridians, promoting qi circulation and relieving pain, and dissolving thrombi and unblocking collaterals," while also addressing the symptoms by tonifying qi and blood and nourishing the liver and kidneys. The herbs work synergistically to treat both the root cause and the symptoms. The preparation method includes steps such as raw material screening and processing, ingredient mixing, decoction extraction, secondary decoction, flavoring, and packaging and storage. The process is simple and low-cost. This TCM has definite efficacy and few side effects, effectively treating injuries from falls and blows, lumbar muscle strain, lumbar disc herniation, cerebral infarction, cerebral hemorrhage, and myocardial infarction. It also improves symptoms such as limb numbness and hemiplegia, solving the problems of limited treatment scope and unstable efficacy in existing TCM formulas, making it suitable for clinical application.

According to the tail end dynamic thrombus rotary removal equipment and the using method thereof, in the working process, under the guidance of the guide wire, the endoscopic pipeline stretches into a blood vessel to conduct thrombus removal operation, thrombus enters the tail end of the endoscopic pipeline, the activated rotary cutting blade conducts rotary cutting and smashing, the thrombus can be directly smashed and sucked out, and the thrombus can be directly removed. The problem of fragmentation residues caused by the fact that traditional suction or stent thrombus extraction can only extrude thrombus is avoided, and the thrombus extraction device is particularly suitable for stubborn thrombus rich in fibrin. The negative pressure value and the parameters of the motor module are accurately set through the touch screen, different thrombus sizes and hardness are adapted, and the defects that a time window needs to be strictly controlled and the bleeding risk exists in the thrombolysis therapy are overcome. The working face of the shaver at the tail end of the endoscopic pipeline is 1-3mm lower than the end face of the outer wall pipe, so that direct contact with the blood vessel wall is avoided; the negative pressure system sucks the chippings into the recovery tank in real time, and the risk of far-end embolism caused by traditional mechanical embolism taking is reduced.

The application discloses a kind of acute cerebral infarction thrombolysis hemorrhage patient treatment combined cold deposit intervention device, it is related to cold deposit infusion technical field, including base, cross transfer box is rotatably connected on base;It also includes infusion hard pipe, infusion hose, fixed plate, first spring, limit frame, drive assembly and fixing mechanism, the end of infusion hose with needle is placed on placement table, infusion hard pipe lower portion is connected with fixed plate, first spring is connected between fixed plate and support, first spring is wound on infusion hard pipe, infusion hard pipe upper portion is connected with limit frame, cross transfer box lower portion is provided with drive assembly, cross transfer box is equipped with the fixing mechanism for clamping and fixing blood bag.The application is first by fixed mechanism to blood bag clamping and fixing, then by drive assembly, realize blood bag automatic replacement, avoid when infusion medical staff cannot leave sickbed, cause medical staff waste, improve the operation convenience of device.

This invention relates to the field of medical device technology, specifically disclosing a thrombus interceptor, comprising a support bladder and a connecting tube. The support bladder has a placement hole and multiple flow holes, the flow holes for blood flow, and the placement holes for accommodating a catheter. The support bladder can abut against the inner wall of a blood vessel after inflating. The connecting tube communicates with the support bladder and can be connected to an external machine to inflate or deflate the support bladder. Contrast agent can be filled into the support bladder. This solution, by using a thrombolytic catheter in conjunction with the interceptor, integrates thrombolysis, thrombectomy, and thrombus interception functions using ultrasound technology. This solves the problems of using metal filters for thrombus interception in existing technologies and enables timely treatment of thrombus patients even in remote areas with limited medical resources.

The present application belongs to the technical field of medical devices, and discloses a medical device, which comprises a joint, a catheter and a guide wire, one end of the catheter is connected with the joint, the guide wire is arranged in the catheter, one end of the guide wire is connected with the joint and the other end of the guide wire extends out of the catheter, the pipe opening of the other end of the guide wire is in a sealed arrangement to prevent the drug liquid injected into the catheter from flowing out of the pipe opening of the other end of the catheter away from the joint, the medical device further comprises an elastic part and a protruding part, the elastic part is sleeved on the other end of the guide wire, the protruding part is sleeved on the outer periphery of the guide wire, the protruding part is connected between the elastic part and the catheter, the diameter of the protruding part is greater than the diameter of the catheter and the elastic part, when the catheter is pulled in the blood vessel, the protruding part not only avoids damaging the medical device, but also effectively reduces the risk of catheterization thrombolysis, and can also crush and dredge the thrombus in advance, so as to increase the contact area of the drug liquid and accelerate the absorption rate of the drug liquid, thereby improving the treatment effect.

This invention discloses a biomarker for early diagnosis, assessment of disease progression, and prognostic evaluation in patients undergoing intravenous thrombolysis for acute ischemic stroke: Syndecan-1 in peripheral blood. This invention provides the application of a substance for detecting Syndecan-1 in peripheral blood in the preparation of products for early diagnosis of prognosis in patients undergoing intravenous thrombolysis for acute ischemic stroke; or in the preparation of products for assessing disease progression in patients undergoing intravenous thrombolysis for acute ischemic stroke; or in the preparation of products for assessing the prognosis of patients undergoing intravenous thrombolysis for acute ischemic stroke. Research results indicate that plasma Syndecan-1 levels represent a novel and independent prognostic biomarker that can improve the current risk stratification of patients undergoing intravenous thrombolysis for acute ischemic stroke. Blood tests are easily accepted by patients and can serve as an effective means for early diagnosis, assessment of disease progression, and prognostic evaluation in patients undergoing intravenous thrombolysis for acute ischemic stroke.

The invention relates to a cerebral apoplexy treatment time window prolonging agent, application of the cerebral apoplexy treatment time window prolonging agent and a cerebral apoplexy thrombolysis kit, and the cerebral apoplexy treatment time window prolonging agent comprises a protein PAI-1 targeting inhibitor, the compound is used for being specifically combined with a plasminogen activator inhibitor PAI-1 released by activated platelets in a cerebral apoplexy thrombus area so as to inhibit the fibrinolytic inhibitory activity of the PAI-1. The invention has the beneficial effects that endogenous fibrinolysis is activated in a safe and effective way, the sharp contradiction between timeliness and safety in the prior art is directly solved, and the medicine is expected to be used as a safe early intervention medicine and provides new treatment possibility for a large number of patients who miss initial treatment opportunities. By means of the exquisite unlocking mechanism, the cerebral apoplexy treatment time window is delayed to 6 h, and precious time is gained for cerebral apoplexy treatment subsequently.

This invention relates to the field of minimally invasive interventional device technology, and particularly to a thrombectomy head and a magnetically controlled microrobot. The thrombectomy head includes a drilling section at the front end and a milling cutting edge connected to the rear end of the drilling section. The milling cutting edge includes at least two milling cutting edge structures, with a chip removal groove between adjacent milling cutting edge structures. This invention achieves graded thrombolysis by combining the drilling section and the milling cutting edge, first breaking up the fragments and then finely grinding them. Combined with the chip removal groove as a chip removal and guiding structure, this improves thrombus removal efficiency while allowing the finely milled small-molecule thrombus fragments to be quickly guided outwards along the chip removal groove with the blood flow. This effectively prevents fragments from accumulating and adhering at the cutting edge, causing head blockage and jamming, and continuously ensuring smooth fluid flow in the cutting area. This further reduces the risk of thrombus fragments re-aggregating and adhering to the blood vessel wall, leading to recurrent embolism, significantly improving thrombolysis smoothness and overall removal efficiency, and further enhancing safety.

Provided is use of anisodine hydrobromide in the preparation of a therapeutic drug for stroke patients after tPA thrombolysis, which can improve various clinical indexes of the patient after thrombolysis for ischemic stroke, repair blood-brain barrier permeability, inhibit leukocyte infiltration, regulate the expression levels of related proteins, etc.

The invention discloses a preparation method of a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, and relates to the technical field of medicines, the pharmaceutical composition comprises a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong According to the preparation method of the pharmaceutical composition for treating the cardiovascular and cerebrovascular diseases, multi-target and multi-layer treatment is realized by comprehensively applying six methods of traditional Chinese medicine, and the cardiovascular and cerebrovascular functions are conditioned fundamentally; the medicine composition has a strong synergistic effect, and can be used for dissolving thrombus and dredging collaterals, repairing vascular endothelium and promoting myocardial cell regeneration; the treatment mode is safe, and western medicine operation wounds and side effects caused by long-term medicine taking are avoided; oral administration and intravenous administration are combined, so that the drug absorption and action persistence are enhanced; the traditional Chinese medicine external treatment method can be matched to further improve the curative effect and realize metabolic balance.

The invention relates to the technical field of medicines, in particular to application of anisodine hydrobromide. Research finds that anisodine hydrobromide after tPA is used has the effect of improving various clinical indexes after ischemic stroke thrombolysis. For example, the polypeptide can repair blood brain barrier permeability, inhibit leukocyte infiltration, regulate related protein expression level and the like.

A method for using metastable perfluorocarbon nanodroplets for ultrasonic lysis of blood clots includes administering metastable perfluorocarbon nanodroplets into a blood vessel that includes or that leads to a blood vessel that includes a blood clot, the metastable perfluorocarbon nanodroplets each have a liquid core comprising a perfluorocarbon material that has a boiling point below 25° C. at atmospheric pressure and that remains stable in liquid form at 25° C. at atmospheric pressure. The method further includes applying ultrasound energy to the perfluorocarbon nanodroplets within or surrounding the blood clot, causing the perfluorocarbon nanodroplets to vaporize and convert to bubbles, which cavitate and lyse the blood clot.

This invention discloses a filter-combined inferior vena cava stent, relating to the field of medical device technology. The stent includes a restraint end and an adjustment end connected to its two ends. A rotating structure for unblocking thrombi is connected between the restraint end and the adjustment end. The adjustment end also includes an adjustment structure for adjusting the mesh size of the adjustment end. This invention can aggregate and unblock thrombi, improving thrombolysis capacity, and can also personalize the mesh size of the filter according to the different blood vessel sizes of different patients.

A configuration method of a mobile ischemic stroke thrombolysis system, the configuration method comprising the following steps: setting respective operation functions according to the characteristics of respective functional components of the mobile ischemic stroke thrombolysis system; building a data transmission network between the functional components to realize transmission and interaction of data parameters; collecting a plurality of parameters of a patient in combination with the calculation results of the operation functions to preliminarily judge the basic information and specific condition of the patient; and summarizing statistical analysis in the mobile ischemic stroke thrombolysis system to generate a processing opinion to obtain a corresponding treatment scheme according to the specific condition of the patient.

The invention discloses a recombinant engineering bacterium, a preparation method thereof and application of the recombinant engineering bacterium in preparation of antithrombotic drugs, and belongs to the technical field of biological medicines. The recombinant engineering bacterium is prepared by taking salmonella typhimurium with relA and spoT gene mutations as a carrier and introducing a recombinant plasmid containing a thrombolytic enzyme coding gene into the carrier. The invention provides a recombinant engineering bacterium with biological safety, the recombinant engineering bacterium has high thrombus targeting property under a dynamic blood flow condition, various thrombus models can be specifically targeted, and the concentration of the recombinant engineering bacterium in thrombus tissues can reach more than ten thousand times of the concentration of normal tissues such as spleen, liver and the like through bacterium proliferation. Through mediated thrombus targeted therapy, thrombus can be effectively dissolved, and revascularization is achieved. The invention provides a more effective and safer treatment strategy for diseases caused by thrombus, such as myocardial infarction, cerebral apoplexy, pulmonary embolism and the like.

The invention discloses a novel arterial thrombus thrombolysis catheter and an application method thereof.The left side and the right side of an I-shaped bearing block are each fixedly provided with a handrail, and the bottoms of the two handrails are fixedly connected with the tops of the adjacent extending cross rods through a plurality of springs. According to the novel arterial thrombus thrombolysis catheter and the application method thereof, through mutual cooperation of the guide hose, the connecting sleeve frame, the position adjusting chute and the extrusion roller, the position of the extrusion roller is adjusted, the extrusion degree of the extrusion roller on the guide hose is changed, airflow passing through the guide hose is changed, then the suction force is controlled, thrombus is better sucked, and the thrombus thrombolysis effect is improved. The self-expanding thrombus suction tube is simple in structure and convenient to use, thrombus rupture or falling caused by too large or too small suction force is avoided, blood can flow out again through meshes in the self-expanding filter screen through mutual cooperation of the tube head, the suction cavity, the self-expanding filter screen and the inner connection catheter, blood supply is guaranteed, and thrombus filtration is achieved.

A system for inducing localized cavitation includes an inducing wire for insertion into a vessel. The including wire has a surface-modified region configured to induce cavitation. The system also includes an ultrasonic transducer configured to deliver ultrasonic energy to a target region that includes the surface-modified region, thereby producing cavitation at a localized region about the surface-modified region. The system may be used intravenously for treatment of thrombi.